| __timestamp | Bausch Health Companies Inc. | Corcept Therapeutics Incorporated |
|---|---|---|
| Wednesday, January 1, 2014 | 2254600000 | 882000 |
| Thursday, January 1, 2015 | 2645000000 | 1361000 |
| Friday, January 1, 2016 | 2611000000 | 2058000 |
| Sunday, January 1, 2017 | 2548000000 | 3554000 |
| Monday, January 1, 2018 | 2351000000 | 5215000 |
| Tuesday, January 1, 2019 | 2350000000 | 5504000 |
| Wednesday, January 1, 2020 | 2249000000 | 5582000 |
| Friday, January 1, 2021 | 2394000000 | 5281000 |
| Saturday, January 1, 2022 | 2364000000 | 5385000 |
| Sunday, January 1, 2023 | 2559000000 | 6481000 |
Cracking the code
In the ever-evolving landscape of the pharmaceutical industry, understanding cost structures is crucial. This analysis delves into the cost of revenue for Corcept Therapeutics Incorporated and Bausch Health Companies Inc. over the past decade.
From 2014 to 2023, Bausch Health's cost of revenue has shown a relatively stable trend, averaging around $2.43 billion annually. The highest cost was recorded in 2015, with a 17% increase from the previous year, while 2020 marked the lowest point.
In contrast, Corcept Therapeutics has experienced a significant upward trajectory. Starting at just $882,000 in 2014, their cost of revenue surged by over 600% to $6.48 million by 2023. This growth reflects Corcept's expanding market presence and operational scale.
These insights highlight the diverse financial strategies and market dynamics within the pharmaceutical sector.
Cost of Revenue Comparison: Johnson & Johnson vs Corcept Therapeutics Incorporated
Analyzing Cost of Revenue: Teva Pharmaceutical Industries Limited and Corcept Therapeutics Incorporated
Cost of Revenue: Key Insights for Neurocrine Biosciences, Inc. and Corcept Therapeutics Incorporated
Insmed Incorporated vs Corcept Therapeutics Incorporated: Efficiency in Cost of Revenue Explored
BioMarin Pharmaceutical Inc. vs Bausch Health Companies Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue: Key Insights for Corcept Therapeutics Incorporated and Alkermes plc
Comparing Cost of Revenue Efficiency: Corcept Therapeutics Incorporated vs Dyne Therapeutics, Inc.
Cost of Revenue Trends: Amneal Pharmaceuticals, Inc. vs Bausch Health Companies Inc.
Analyzing Cost of Revenue: Perrigo Company plc and Bausch Health Companies Inc.
Cost Insights: Breaking Down Bausch Health Companies Inc. and Vericel Corporation's Expenses
Comparing Cost of Revenue Efficiency: Bausch Health Companies Inc. vs Mesoblast Limited